Medical Condition News

RSS

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.

27 Oct 2010

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Sirius receives U.S. patent for using SNP in Protein C gene

Sirius Genomics, a developer of companion diagnostics, announced today that U.S. Patent 7,820,376 entitled "Protein C Polymorphisms" has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.

27 Oct 2010

Pledge to reduce antipsychotic use in dementia sufferers

A new coalition of 44 organizations called the Dementia Action Alliance, has called for a cut in the use of anti-psychotic drugs for patients with dementia. The coalition includes Alzheimer's Research Trust, Alzheimer's Society, BUPA, Dementia UK, the Royal College of Psychiatrists, Royal College of General Practitioners and Stroke Association.

26 Oct 2010

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

26 Oct 2010

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Infinity Pharmaceuticals, Inc. today announced that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., have exercised their right to assume worldwide development and commercialization activities for Infinity's fatty acid amide hydrolase, or FAAH, program. The decision reflects progress made in the development of Infinity's oral FAAH inhibitor, IPI-940.

26 Oct 2010

miRagen and CU enter agreement on miRNA therapeutics discovery and development

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and the University of Colorado (CU) announced today that they have entered into sponsored research and licensing agreements to collaborate on miRNA therapeutics discovery and development.

26 Oct 2010

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a 4 week Phase 1 trial of its new self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis.

26 Oct 2010

New findings could deliver low-cost method to extract anticancer compound

A popular cancer drug could be produced cheaply and sustainably using stem cells derived from trees, a study suggests. Researchers have isolated and grown stem cells from a yew tree whose bark is a natural source of the anticancer compound paclitaxel. The development could enable the compound to be produced on a commercial scale at low cost, with no harmful by-products.

26 Oct 2010

Research indicates stroma tissue provides new drug target for treating pancreatic cancer

A project focusing on the scar tissue surrounding cancer tumours aims to provide new targets for drugs for treating pancreatic cancer, the fifth highest cause of cancer deaths in the UK.

26 Oct 2010

Prevention of vascular diseases needed to avoid tsunami of cases

Canada urgently needs to focus on prevention of vascular diseases to avoid the burden from the expected tsunami of cases, says noted stroke expert Dr. Robert Côté, delivering the Heart and Stroke Foundation of Canada (HSFC) Lecture at the Canadian Cardiovascular Congress 2010.

26 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

Potential technologies to help older people sleep better

The Somnia conference has been led by academics at the University of Surrey in conjunction with other academics including those working on new technology at the University of Bath.

26 Oct 2010

Neurologix holds license for gene therapy to treat severe depression

Neurologix, Inc. today announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights. Based on the findings reported in the paper, gene therapy may have potential as a new treatment option for people who suffer from severe depression.

26 Oct 2010

DGAC Report highlights effective approaches to facilitate better eating habits among Americans

In an insightful Commentary in the November issue of the Journal of the American Dietetic Association, Linda Van Horn, PhD, RD, Editor-in-Chief of the Journal, Chair of the Dietary Guidelines Advisory Committee, and Professor and Associate Dean, Northwestern University, Feinberg School of Medicine, highlights the key features and noteworthy findings of the 2010 US Dietary Guidelines Advisory Committee (DGAC) Report.

26 Oct 2010

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. Their research showed that the Notch pathway and Hes1 gene play a key role in promoting the metastasis of osteosarcoma, the most common form of bone cancer in children.

26 Oct 2010

Contraband tobacco accounts for 43% of cigarettes consumed by Ontario students

A new study from The Centre for Addiction and Mental Health (CAMH) found that contraband tobacco accounts for 43% of all cigarettes consumed by Ontario high school daily smokers in grades 9 to 12.

26 Oct 2010

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of renal cell carcinoma (RCC), the majority of surveyed European oncologists who favor Pfizer's Sutent indicate that they would switch to an emerging therapy only if it extended progression-free survival (PFS) by at least an additional two to three months, assuming the agent's safety and tolerability profile was comparable to that of Sutent.

26 Oct 2010

NAA applauds IACC's decision on safety issues in autism community

The National Autism Association (NAA) is applauding the Interagency Autism Coordinating Committee (IACC) today following the Committee's decision late Friday to instate a subcommittee dedicated to safety issues within the autism community.

26 Oct 2010

New source of blood-derived biomarkers may help in cancer diagnosis

The future of cancer diagnosis may lie in just a few milliliters of blood, according to a research team led by Professor Arie Admon of the Technion-Israel Institute of Technology.

26 Oct 2010

Medical Condition News

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

Sirius receives U.S. patent for using SNP in Protein C gene

Pledge to reduce antipsychotic use in dementia sufferers

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

miRagen and CU enter agreement on miRNA therapeutics discovery and development

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

New findings could deliver low-cost method to extract anticancer compound

Research indicates stroma tissue provides new drug target for treating pancreatic cancer

Prevention of vascular diseases needed to avoid tsunami of cases

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Potential technologies to help older people sleep better

Neurologix holds license for gene therapy to treat severe depression

DGAC Report highlights effective approaches to facilitate better eating habits among Americans

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Contraband tobacco accounts for 43% of cigarettes consumed by Ontario students

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

NAA applauds IACC's decision on safety issues in autism community

New source of blood-derived biomarkers may help in cancer diagnosis

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Latest News